# Bortezomib to Treat Significant Complication of HSCT

> **NCT01929980** · PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 4 (actual)

## Conditions studied

- Allogeneic Stem Cell Transplantation
- Refractory Autoimmune Cytopenia(s)

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01929980
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2016-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929980, "Bortezomib to Treat Significant Complication of HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01929980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*